Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated

The Biology of Aromatase Deficiency

At a Glance

Aromatase deficiency is an inherited condition caused by changes in the CYP19A1 gene. The body makes too little estrogen and too much unconverted androgen, so newborns with atypical genitalia must be checked urgently for the life-threatening adrenal form of CAH.

Understanding the biology of aromatase deficiency is like looking at a complex chemical roadmap where one critical bridge has been washed away. While the name sounds technical, the underlying mechanism is a straightforward problem of conversion and balance.

The Aromatase “Bridge”

The CYP19A1 gene provides the body with instructions to create an enzyme called aromatase [1]. Enzymes are specialized proteins that speed up chemical reactions in the body. Aromatase’s specific job is to act as a bridge that converts androgens (such as testosterone and androstenedione) into estrogens (such as estradiol and estrone) [2][3]. Both of these hormone types are present and necessary in all bodies.

When someone has aromatase deficiency, this bridge is either broken or missing due to a genetic mutation. This leads to two simultaneous biological events:

  1. Estrogen Shortage: The body cannot produce enough estrogen, which is essential for bone strength, growth plate closure, and typical pubertal development [4][5].
  2. Androgen Buildup: The hormones that were supposed to be converted—the androgens—begin to back up and accumulate, like water behind a dam [6][7].

An Autosomal Recessive Condition

Aromatase deficiency is an autosomal recessive disorder [6]. This means a person must inherit two copies of the mutated gene—one from each parent—to have the condition [8].

  • Carriers: Parents are typically “carriers,” meaning they have one mutated gene and one working gene. Carriers usually have enough aromatase activity to function normally and do not show symptoms [9].
  • The Inheritance Pattern: When two carriers have a child, there is a 25% chance the child will inherit two mutated genes and have the condition.

Distinguishing Aromatase Deficiency from CAH

When a baby is born with ambiguous or atypical genitalia, doctors must move quickly. Their first priority is almost always ruling out Congenital Adrenal Hyperplasia (CAH), specifically the 21-hydroxylase deficiency form [10][11].

An infant with atypical genital development cannot safely be assumed to have aromatase deficiency until salt-wasting CAH and other dangerous causes are excluded. A normal newborn screen does not rule out every form of CAH. Urgent clinical assessment is required.

Feature Aromatase Deficiency 21-Hydroxylase CAH
Emergency Risk Low (no adrenal crisis once diagnosed) [12] High (Life-threatening “salt-wasting”) [13]
Hormone Profile Low Estrogen, High FSH [14] High 17-OHP, Low Cortisol [10]
Primary Issue Conversion of androgens [2] Production of cortisol/aldosterone [15]
Newborn Screen Often missed/normal [12] Usually detected by 17-OHP levels [10]

Why CAH is the priority: In the “salt-wasting” form of CAH, the body cannot produce cortisol and aldosterone, which help maintain salt and water balance. This can lead to a life-threatening crisis in the first days of life, involving dehydration and dangerous heart rhythms [13][15]. Urgent evaluation often involves testing electrolytes, glucose, blood pressure, 17-OHP, cortisol, and renin/aldosterone. Because aromatase deficiency only affects sex hormones and not adrenal function, it is not life-threatening in the same way, but it can “mimic” the physical appearance of CAH at birth [16][12].

CYP19A1 vs. POR Dysfunction

Sometimes, the problem isn’t the aromatase enzyme itself, but the “power supply” that helps it work. This is called P450 oxidoreductase (POR) deficiency [17].

  • Isolated CYP19A1 Deficiency: Only the aromatase bridge is broken. The body’s other hormone pathways (like cortisol) work fine [18].
  • POR Dysfunction: POR is a helper protein that provides energy to multiple enzymes, including aromatase and the enzymes involved in CAH [19]. Because POR affects many pathways at once, it can cause a broader range of symptoms, including unique skeletal differences (like craniosynostosis, where skull bones fuse too early) that are not seen in pure aromatase deficiency [20][21].

Vital Terms to Know

  • 46,XX / 46,XY: The typical chromosomal patterns.
  • Virilization: The development of more masculinized physical characteristics (like increased hair growth or atypical genitalia) caused by excess androgens [7].
  • 17-OHP (17-hydroxyprogesterone): A chemical building block for hormones. It is very high in CAH but can sometimes be slightly elevated in aromatase deficiency, which can lead to initial diagnostic confusion [10][12].
  • FSH (Follicle-Stimulating Hormone): A hormone from the brain that tells the ovaries or testes to work. It is often very high in aromatase deficiency because the brain is “shouting” for the body to make the estrogen it’s missing [14].

Common questions in this guide

What happens in the body when someone has aromatase deficiency?
A change in the CYP19A1 gene reduces aromatase, the enzyme that normally converts androgens such as testosterone into estrogens. As a result, estrogen levels may be low while unconverted androgens build up, affecting bone development and typical puberty.
How is aromatase deficiency inherited?
Aromatase deficiency follows an autosomal recessive inheritance pattern, so a person usually needs two altered copies of CYP19A1 to have the condition. When both parents are carriers, each pregnancy has a 25% chance of resulting in a child with the condition.
Why do doctors check for CAH first when a newborn has atypical genitalia?
Salt-wasting congenital adrenal hyperplasia, or CAH, can prevent the body from making enough cortisol and aldosterone and may cause a life-threatening adrenal crisis soon after birth. Aromatase deficiency can resemble CAH in appearance but does not cause the same adrenal emergency, so urgent testing is needed to distinguish them.
Which hormone results can help distinguish aromatase deficiency from CAH?
Aromatase deficiency is associated with low estrogen and often high FSH because the brain signals for more estrogen production. 21-hydroxylase CAH is more associated with high 17-OHP and low cortisol, and clinicians may also check electrolytes, glucose, blood pressure, and renin or aldosterone when salt-wasting is a concern.
How is POR deficiency different from CYP19A1 deficiency?
Isolated CYP19A1 deficiency mainly affects aromatase and the conversion of androgens into estrogens. POR is a helper protein for several hormone-producing enzymes, so POR deficiency can affect multiple pathways and may be associated with skeletal differences such as craniosynostosis.
What do homozygous and compound heterozygous mean on a genetic report?
Homozygous means that the same gene variant is present in both copies of CYP19A1. Compound heterozygous means that two different variants are present, usually one in each copy; a genetics professional must determine whether the specific variants explain the condition.

Get notified when new evidence is published on Aromatase deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (21)
  1. 1

    Aromatase deficiency in a male patient - Case report and review of the literature.

    Miedlich SU, Karamooz N, Hammes SR

    Bone 2016; (93()):181-186 doi:10.1016/j.bone.2016.09.024.

    PMID: 27693882
  2. 2

    Congenital disorders of estrogen biosynthesis and action.

    Fukami M, Ogata T

    Best practice & research. Clinical endocrinology & metabolism 2022; (36(1)):101580 doi:10.1016/j.beem.2021.101580.

    PMID: 34538723
  3. 3

    QM/MM modeling of the hydroxylation of the androstenedione substrate catalyzed by cytochrome P450 aromatase (CYP19A1).

    Viciano I, Castillo R, Martí S

    Journal of computational chemistry 2015; (36(23)):1736-47 doi:10.1002/jcc.23967.

    PMID: 26096372
  4. 4

    Aromatase deficiency in a tall man: Case report of two novel mutations and review of literature.

    Singhania P, Dash D, Dhar A, et al.

    Bone reports 2022; (17()):101642 doi:10.1016/j.bonr.2022.101642.

    PMID: 36504506
  5. 5

    Accelerated Pubertal Tempo in a 46,XY Aromatase-Deficient Patient.

    Costanzo M, Garcia-Feyling J, Saraco N, et al.

    Hormone research in paediatrics 2018; (90(4)):275-282 doi:10.1159/000492128.

    PMID: 30173221
  6. 6

    Aromatase deficiency: a novel compound heterozygous mutation identified in a Chinese girl with severe phenotype and obvious maternal virilization.

    Zhu WJ, Cheng T, Zhu H, et al.

    Molecular and cellular endocrinology 2016; (433()):66-74.

    PMID: 27256151
  7. 7

    Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature.

    Fan L, Zhang B, Li L, Gong C

    Clinical endocrinology 2020; (93(6)):687-695 doi:10.1111/cen.14277.

    PMID: 32623730
  8. 8

    A Novel Homozygous CYP19A1 Gene Mutation Causing Aromatase Deficiency.

    Hathi D, Goswami S, Sengupta N, Baidya A

    Cureus 2022; (14(2)):e22059 doi:10.7759/cureus.22059.

    PMID: 35340461
  9. 9

    A Novel Null Mutation in P450 Aromatase Gene (CYP19A1) Associated with Development of Hypoplastic Ovaries in Humans.

    Akçurin S, Türkkahraman D, Kim WY, et al.

    Journal of clinical research in pediatric endocrinology 2016; (8(2)):205-10 doi:10.4274/jcrpe.2761.

    PMID: 27086564
  10. 10

    Genetics and Pathophysiology of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.

    Yang M, White PC

    The Journal of clinical endocrinology and metabolism 2025; (110(Supplement_1)):S1-S12 doi:10.1210/clinem/dgae535.

    PMID: 39836621
  11. 11

    46,XX DSD due to Androgen Excess in Monogenic Disorders of Steroidogenesis: Genetic, Biochemical, and Clinical Features.

    Baronio F, Ortolano R, Menabò S, et al.

    International journal of molecular sciences 2019; (20(18)) doi:10.3390/ijms20184605.

    PMID: 31533357
  12. 12

    A Novel Homozygous CYP19A1 Gene Mutation: Aromatase Deficiency Mimicking Congenital Adrenal Hyperplasia in an Infant without Obvious Maternal Virilisation

    Dursun F, Ceylaner S

    Journal of clinical research in pediatric endocrinology 2019; (11(2)):196-201 doi:10.4274/jcrpe.galenos.2018.2018.0140.

    PMID: 30074481
  13. 13

    The presentation of congenital adrenal hyperplasia in an unscreened population.

    Conlon TA, Hawkes CP, Brady JJ, Murphy NP

    Journal of pediatric endocrinology & metabolism : JPEM 2021; (34(9)):1123-1129 doi:10.1515/jpem-2021-0123.

    PMID: 34167176
  14. 14

    46,XX aromatase deficiency: A single-center experience with the varied spectrum and recurrent variants, and a systematic review of hormonal parameters.

    Yami Channaiah C, Memon SS, Sarathi V, et al.

    Annales d'endocrinologie 2024; (85(1)):48-55 doi:10.1016/j.ando.2023.05.010.

    PMID: 37348676
  15. 15

    Congenital adrenal hyperplasia with salt-wasting crisis and arrhythmia: a case study.

    Canlas JF, Ponmani C

    BMJ case reports 2019; (12(1)) doi:10.1136/bcr-2018-227565.

    PMID: 30700462
  16. 16

    Child with '46, XX' disorder of sex development: clues to diagnose aromatase deficiency.

    Agrawal SS, Chakraborty PP, Sinha A, Maiti A

    BMJ case reports 2019; (12(12)) doi:10.1136/bcr-2019-232575.

    PMID: 31801784
  17. 17

    Long-term follow-up of a female with congenital adrenal hyperplasia due to P450-oxidoreductase deficiency.

    Bonamichi BD, Santiago SL, Bertola DR, et al.

    Archives of endocrinology and metabolism 2016; (60(5)):500-504 doi:10.1590/2359-3997000000213.

    PMID: 27737328
  18. 18

    Novel CYP19A1 Mutations Extend the Genotype-Phenotype Correlation and Reveal the Impact on Ovarian Function.

    Praveen VP, Ladjouze A, Sauter KS, et al.

    Journal of the Endocrine Society 2020; (4(4)):bvaa030 doi:10.1210/jendso/bvaa030.

    PMID: 32318648
  19. 19

    Disordered Electron Transfer: New Forms of Defective Steroidogenesis and Mitochondriopathy.

    Miller WL, Pandey AV, Flück CE

    The Journal of clinical endocrinology and metabolism 2025; (110(3)):e574-e582 doi:10.1210/clinem/dgae815.

    PMID: 39574227
  20. 20

    Bone Disease Associated with Inactivating Aromatase Mutations and its Management.

    Cavati G, Merlotti D, Cardamone P, et al.

    Calcified tissue international 2025; (116(1)):14 doi:10.1007/s00223-024-01330-0.

    PMID: 39751875
  21. 21

    Clinical, endocrinological, and molecular features of four Korean cases of cytochrome P450 oxidoreductase deficiency.

    Lee Y, Choi JH, Oh A, et al.

    Annals of pediatric endocrinology & metabolism 2020; (25(2)):97-103 doi:10.6065/apem.1938152.076.

    PMID: 32615689

This page explains the genetics and hormone biology of aromatase deficiency for informational purposes only and does not constitute medical advice. Prompt clinical evaluation is essential for atypical genitalia in a newborn, and a clinician should interpret your family’s hormone and genetic results.

Guide contents Aromatase deficiency
Research & Literature
01 Understanding Your Aromatase Deficiency Diagnosis 03 Symptoms and Clinical Signs Across the Lifespan